Powered By Bing

Supplementary Information

Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia

Section I: Patient Dataset

Table S1. Pediatric AML sample characteristics

Case identifier subtypea MLL statusb FABc Sampled % Blastse Protocolf
inv16-#01 CBFβ-MYH11   M4E BM 94 AML83
inv16-#02 CBFβ-MYH11   M4 BM 98 AML87
inv16-#03 CBFβ-MYH11   M4E BM 89 AML87
inv16-#04 CBFβ-MYH11   M4 BM 80 AML91
inv16-#05 CBFβ-MYH11   M4E BM 85 AML91
inv16-#06 CBFβ-MYH11   M4 BM 77 AML91
inv16-#07 CBFβ-MYH11   M4E BM 85 AML97
inv16-#08 CBFβ-MYH11   M4E BM 88 AML97
inv16-#09 CBFβ-MYH11   M4E BM 89 AML87
inv16-#10 CBFβ-MYH11   M4E BM 79 AML97
inv16-#11 CBFβ-MYH11   M1 BM 88 AML97
inv16-#12 CBFβ-MYH11   M4E BM 86 AML97
inv16-#13 CBFβ-MYH11   M1E BM 96 AML83
inv16-#14 CBFβ-MYH11   M4E BM 66 non protocol
MLL-#01 MLL t(11;19) M4 BM 91 AML87
MLL-#02 MLL t(9;11) M5a BM 73 AML87
MLL-#03 MLL t(6;11) M5b BM 96 AML91
MLL-#04 MLL t(3;11) M5a BM 94 AML91
MLL-#05 MLL t(1;11) M5a PB 88 AML91
MLL-#06 MLL t(10;11) M5a BM 77 AML91
MLL-#07 MLL t(9;11) M5a BM 96 AML91
MLL-#08 MLL t(9;11) M5a BM 88 AML91
MLL-#09 MLL t(7;9;11) M5a BM 92 AML91
MLL-#10 MLL t(9;11) M5a BM 80 AML91
MLL-#11 MLL t(11;19) M5b PB 90 AML91
MLL-#12 MLL t(9;11) M5a BM 87 AML91
MLL-#13 MLL t(1;11) M5a BM 98 AML91
MLL-#14 MLL t(11;19) M1 BM 95 AML97
MLL-#15 MLL t(1;11) M5a BM 90 AML97
MLL-#16 MLL t(10;11) M5a apheresis 97 AML97
MLL-#17 MLL t(9;11) M5a BM 97 AML97
MLL-#18 MLL t(9;11) M1 BM 96 AML97
MLL-#19 MLL t(10;11) M5a BM 70 AML97
MLL-#20 MLL t(11;16) M5b BM 88 AML91
MLL-#21 MLL t(9;11) M5a BM 96 AML87
MLL-#22 MLL t(4;11) M5a PB 97 AML97
MLL-#23 MLL t(10;11) M5a PB 71 AML97
t(15:17)-#01 PML-RARα   M3 BM 95 AML87
t(15:17)-#02 PML-RARα   M3 PB 88 AML83
t(15:17)-#03 PML-RARα   M3 BM 89 PG9220
t(15:17)-#04 PML-RARα   M3 BM 83 non protocol
t(15:17)-#05 PML-RARα   M3 BM 95 non protocol
t(15:17)-#06 PML-RARα   M3 BM 88 PG9710
t(15:17)-#07 PML-RARα   M3 PB 87 El-Salvador
t(15:17)-#08 PML-RARα   M3 BM 91 El-Salvador
t(15:17)-#09 PML-RARα   M3 BM 97 El-Salvador
t(15:17)-#10 PML-RARα   M3 BM 87 non protocol
t(15:17)-#11 PML-RARα   M3 BM 94 PG9710
t(15:17)-#12 PML-RARα   M3 BM 90 PG9710
t(15:17)-#13 PML-RARα   M3 BM 93 non protocol
t(15:17)-#14 PML-RARα   M3 BM 92 non protocol
t(15:17)-#15 PML-RARα   M3 BM 93 AML87
t(8:21)-#01 AML1-ETO   M2 BM 74 AML87
t(8:21)-#02 AML1-ETO   M4E BM 91 AML87
t(8:21)-#03 AML1-ETO   M2 BM 81 AML87
t(8:21)-#04 AML1-ETO   M2 BM 72 AML87
t(8:21)-#05 AML1-ETO   M2 BM 88 AML87
t(8:21)-#06 AML1-ETO   M2 BM 76 AML91
t(8:21)-#07 AML1-ETO   M2 BM 83 AML97
t(8:21)-#08 AML1-ETO   M2 BM 92 AML97
t(8:21)-#09 AML1-ETO   M2 BM 93 AML97
t(8:21)-#10 AML1-ETO   M2 BM 92 AML97
t(8:21)-#11 AML1-ETO   M2 BM 90 AML97
t(8:21)-#12 AML1-ETO   M2 BM 90 AML97
t(8:21)-#13 AML1-ETO   M2 BM 79 El-Salvador
t(8:21)-#14 AML1-ETO   M2 BM 95 El-Salvador
t(8:21)-#15 AML1-ETO   M2 BM 90 El-Salvador
t(8:21)-#16 AML1-ETO   M1 BM 92 El-Salvador
t(8:21)-#17 AML1-ETO   M2E BM 80 El-Salvador
t(8:21)-#18 AML1-ETO   M1 BM 91 AML97
t(8:21)-#19 AML1-ETO   M2 BM 89 AML97
t(8:21)-#20 AML1-ETO   M2E PB 99 AML87
t(8:21)-#21 AML1-ETO   M2 BM 76 non protocol
Other-#01 Other   M1 BM 93 AML87
Other-#02 Other   M2 BM 98 AML87
Other-#03 Other MLL- PTD M1 BM 93 AML87
Other-#04 Other   M4E BM 80 AML80
Other-#05 Other   M1 BM 93 AML87
Other-#06 Other   M1 BM 88 AML87
Other-#07 Other MLL- PTD M2 PB 84 AML87
Other-#08 Other MLL- PTD M2 BM 92 AML87
Other-#09 Other MLL- PTD M2 BM 81 AML87
Other-#10 Other   M2 BM 93 AML84
Other-#11 Other   M1 BM 95 AML87
Other-#12 Other   M2 BM 85 AML87
Other-#13 Other MLL- PTD M2 BM 83 AML91
Other-#14 Other   M1 BM 93 AML91
Other-#15 Other MLL- PTD M2 BM 75 AML91
Other-#16 Other MLL- PTD M1 BM 85 AML91
Other-#17 Other   M1 BM 89 AML91
Other-#18 Other   M4 BM 93 AML97
Other-#19 Other   M2 BM 94 AML91
Other-#20 Other MLL- PTD M1 BM 96 AML91
Other-#21 Other   M1 BM 84 AML91
Other-#22 Other MLL- PTD M2 BM 78 AML91
Other-#23 Other   M1 BM 95 AML97
Other-#24 Other   M4E BM 85 AML97
Other-#25 Other   M1 BM 87 AML97
Other-#26 Other MLL- PTD M4 BM 93 AML97
Other-#27 Other   M1 BM 92 AML97
Other-#28 Other   M1 BM 98 AML97
Other-#29 Other   M1 BM 74 AML97
Other-#30 Other   M2 BM 86 AML97
Other-#31 Other   M1 BM 80 AML97
Other-#32 Other   M2 BM 78 AML97
Other-#33 Other MLL- PTD M5a BM 92 AML87
Other-#34 Other   M5a BM 93 AML87
Other-#35 Other   M4 BM 82 AML91
Other-#36 Other   M5a BM 72 AML97
Other-#37 Other   M1 BM 95 AML97
Other-#38 Other   M1 BM 92 AML97
Other-#39 Other   M5a BM 90 AML97
Other-#40 Other   M5a BM 76 AML97
Other-#41 Other   M1 BM 89 AML97
Other-#42 Other MLL- PTD M2 BM 85 AML97
Other-#43 Other MLL- PTD M4 BM 80 AML97
Other-#44 Other   M4 BM 81 AML91
Other-#45 Other   M2 BM 77 AML91
Other-#46 Other   M1 BM 92 AML83
Other-#47 Other   M2 PB 95 AML83
Other-M7-#01 FAB-M7   M7 BM 82 AML87
Other-M7-#02 FAB-M7   M7 BM 78 AML87
Other-M7-#03 FAB-M7   M7 BM 78 non protocol
Other-M7-#04 FAB-M7   M7 BM 50 AML97
Other-M7-#05 FAB-M7   M7 BM 80 AML97
Other-M7-#06 FAB-M7   M7 BM 68 AML97
Other-M7-#07 FAB-M7   M7 BM 90 AML91
Other-M7-#08 FAB-M7   M7 PB 73 AML91
Other-M7-#09 FAB-M7   M7 BM 97 non protocol
Other-M7-#10 FAB-M7   M0* BM 80 AML83

a AML subtype cases were assigned to for this analysis. Translocation was determined by at least two methods: cytogenetics, FISH, and/or RT-PCR.
b MLL status:  MLL-PTD is partial tandem duplication, or translocation partner is indicated for reciprocal translocations.
c French-American British type as reviewed by M.Onciu. No examples of FAB-M3 variant were included.
d type of specimen evaluated: BM = bone marrow; PB = peripheral blood.
e Percent blast in diagnostic specimen post-ficoll purification.
f treatment protocols: AML83, AML87, AML91, AML97 are St. Jude Chilren's Research Hospital institutional protocols.  PG9710 Pediatric Oncology Cooperative Group study.

El Salvador refers to patients treat in El Salvador through St. Jude's International Outreach Program.
* morphologically and cytochemically this case was suggestive of FAB-M7.  CD41 was negative but no other megakaryocytic markers were evaluated.  This case was treated as FAB-M7 for purposes of these analyses.